<DOC>
	<DOCNO>NCT01128387</DOCNO>
	<brief_summary>The overall study objective evaluate dose limit toxicity recommend phase II dose Panitumumab combine standard care treatment cisplatin , fluorouracil radiation patient locally advanced esophageal cancer . The investigator also assess ability PET image predict degree pathologic response . All patient pre-study FDG PET scan receive radiation therapy chemotherapy 35 day period . 4-8 week post radiation chemotherapy patient restaged PET/CT scan . It anticipate approximately 30 patient enrol undergo esophagectomy consider standard care post radiation chemotherapy . The surgery allow u compare study regimen historical standard care ( Cisplatin/fluorouracil chemotherapy radiation therapy ) .</brief_summary>
	<brief_title>Trial Panitumumab/Cisplatin/Fluorouracil With XRT Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Locally Advanced Esophageal cancer ( stage T1N1 T24 N ) 2 . Histology must adenocarcinoma squamous cell carcinoma 3 . Must surgical candidate base evaluation thoracic surgeon 4. must adequate organ function define routine lab test 1 . Insitu carcinoma 2. prior chemotherapy esophageal cancer 3 . Metastatic ( stage IV disease ) 4 . Tumors &lt; 5cm cricopharyngeus muscle , Tumors &gt; 75 % tumor locate within stomach 5 . Active , uncontrolled cardiac disease 6. subject &gt; Grade 2 neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>Locally advanced esophageal cancer</keyword>
</DOC>